An Arizona cancer patient has filed a new lawsuit over hair loss after chemotherapy against Sanofi Aventis, alleging that she was not adequately warned of the risk.

The plaintiff, Nancy M., says she began treatment with the chemo drug Taxotere in August 2007, continuing for a few months through that November. Unfortunately, Nancy alleges that she experienced “significant” hair loss after chemotherapy was over.

Of course, hair loss is one of the most widely recognized side effects of chemotherapy, so patients generally go into their cancer treatment aware that they may suffer from hair loss during treatment. However, patients may not be aware that certain chemotherapy drugs, including Taxotere, are associated with more persistent problems with hair loss after chemotherapy is over.

Indeed, Nancy claims that even now, more than a decade after her cancer treatment with Taxotere ended thather hair has not grown back to the same quality it was prior to chemotherapy.

According to Nancy’s lawsuit, she should have been warned not just about the risk of hair loss from cancer treatment, but about the possibility of more permanent problems with hair loss after chemotherapy is over.

Nancy turned to litigation, filing a lawsuit against Sanofi-Aventis on April 12, 2018, in the U.S. District Court for the Eastern District of Louisiana. Nancy filed the lawsuit on multiple counts, including failure to warn, negligence, fraudulent misrepresentation and concealment, and others.

Nancy’s is far from the first lawsuit to be filed over persistent hair loss after chemotherapy treatment. If you have suffered from hair loss after chemotherapy (also known as alopecia), you may be eligible to file a lawsuit and receive compensation.

Background of Taxotere

Taxotere (also known by its generic name, docetaxel) is a popular chemotherapy drug manufactured by pharmaceutical giant Sanofi-Aventis. Since Taxotere’s approval by the U.S. Food and Drug Administration (FDA) in 1996, it has become one of the more popular chemotherapy drugs available on the market today.

Unfortunately, Taxotere is not without its risks. More and more patients are coming forward with allegations that Taxotere carries a higher risk of persistent hair loss after chemotherapy than other options, and that they were not adequately warned about this risk.

Hair Loss After Chemotherapy

Hair loss is a common symptom associated with chemotherapy treatment—and indeed, the majority of cancer patients go into treatment aware that they will likely lose their hair. However, patients generally expect that their hair will grow back once their chemotherapy treatment is over. But a growing number of cancer patients like Nancy are finding their permanent problems with hair loss after chemotherapy to be much more lasting in nature than they ever expected.

Filing a Lawsuit Over Hair Loss After Chemotherapy

If you or someone you love has suffered from persistent hair loss after chemotherapy with a docetaxel medication like Taxotere, you may be able to file or join a lawsuit.

Filing a Taxotere lawsuit cannot take away the pain and suffering a cancer patient endures or take away the effects of persistent hair loss after chemo, but it can help compensate for the financial expenses incurred by cancer treatment bills or even lost wages.

The Hair Loss After Chemotherapy Lawsuit is Case No. 2:18-cv-03869-KDE-MBN, in the U.S. District Court for the Eastern District of Louisiana.